article Progression, trends and industry leaders in HIV and AIDS research 6 December 2019 | By Hannah Balfour (Drug Target Review) HIV is a disease still common in sub-Saharan Africa despite global research since 1982. This article delves into the trends, opportunities and key players in HIV research, exploring future possibilities for treating the disease.
webinar Harmonising drug-target binding data analytics on a single platform 6 November 2018 | By PerkinElmer This webinar outlined the fundamentals of a design process where an experimental analytics data workflow is being integrated into a more seamlessly interactive platform...
news Link between TB and Parkinson’s disease identified 23 May 2018 | By Dr Zara Kassam (Drug Target Review) The mechanism our immune cells use to clear bacterial infections like tuberculosis might also be implicated in Parkinson's disease...
news An interview with Bjorg K. Hunter, Device Engineering Manager from GSK ahead of Pre-Filled Syringes Europe 2018 20 November 2017 | By SMi Group A debate on the impact of PFS regulation at Pre-Filled Syringes 2018...
news Discovery of ‘mini-brains’ could change understanding of pain medication 5 April 2017 | By Niamh Marriott (Drug Target Review) The human body’s peripheral nervous system could be capable of interpreting its environment and modulating pain, neuroscientists have established, after successfully studying how rodents reacted to stimulation.
article GSK: A Lifetime in Fluorescence 4 April 2017 | By Carl Haslam, Gabriella Clarke, Luke Greenhough, Peter D Craggs, Ryan P Bingham GSK's top investigators explain why the data quality offered by Fluorescence lifetime detection technology for drug discovery applications is superior…
news Big pharma establishes new industry standards group 16 January 2017 | By Niamh Marriott (Drug Target Review) Pharma companies involved include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis, and Pfizer.
news First female CEO to lead GSK as Emma Walmsley succeeds Andrew Witty 20 September 2016 | By Niamh Louise Marriott, Digital Content Producer Emma Walmsley will succeed Andrew Witty as GSK CEO when he retires on 31st March 2017, making her the first female CEO of a major pharmaceuticals company...
news ‘Library’ of de-prioritised pharma compounds available for researchers 16 September 2016 | By Niamh Marriott (Drug Target Review) UK scientists can apply for MRC funding to use any of the compounds in medical research studies to investigate the underlying mechanics of disease...
news GlaxoSmithKline to invest £275 million in UK 27 July 2016 | By Niamh Louise Marriott, Digital Content Producer The investment will be used for manufacturing of new respiratory and biopharmaceuticals, to be exported outside the UK to global markets...
news Prospective biobank studies can help improve drug development 15 June 2016 | By Victoria White, Digital Content Producer According to a study, genetic research in large-scale prospective biobank studies can significantly improve the drug development pipeline and reduce costs...
news Scientists discover a faster way to synthesise antibiotics 4 May 2016 | By Victoria White, Digital Content Producer By expressing the genes involved in the production of pleuromutilin in a different type of fungus, researchers increased production by more than 2,000%...
news Vaccines and alternatives can play a role in tackling drug-resistant infections 12 February 2016 | By Victoria White The latest report from the Review on Antimicrobial Resistance says that vaccines and other alternatives can play a vital role in tackling the rise of drug-resistant infections...
news Adaptimmune and GSK expand cancer immunotherapy collaboration 3 February 2016 | By Victoria White The enhanced agreement will accelerate Adaptimmune’s lead clinical cancer programme, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1...
news ADDoPT project set to transform the UK pharma industry 28 January 2016 | By Victoria White The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
